|
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we assessed MET expression and mutation status in primary and metastatic lesions within a cohort of patients with advanced HNSCC.
|
31744898 |
2020 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
KEY POINTS: This case report is believed to be the first reported pan-cancer case of a patient harboring a <i>MET</i> mutation at R1004 demonstrating a clinical response to crizotinib, in addition to the first documented case of head and neck squamous cell carcinoma (HNSCC) with any <i>MET</i> alteration responding to crizotinib.The positive response to MET inhibition in this patient highlights the significance of comprehensive genomic profiling in advanced metastatic HNSCC to identify actionable targetable molecular alterations as current treatment options are limited.
|
31391294 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stimulation of MET in HNSCC cell lines was sufficient to reactivate the MAPK pathway and to confer resistance to cetuximab in vitro and in vivo.
|
30694565 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MET expression in HNSCC cells was not always associated with activity/phosphorylation.
|
30552828 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
We and others have demonstrated that cetuximab resistance in HNSCC is driven by alternative receptor tyrosine kinases (RTK), including HER3, MET, and AXL.
|
29792310 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The hepatocyte growth factor receptor; also known as mesenchymal-epithelial transition factor (c-Met) and its ligand hepatocyte growth factor (HGF) are overexpressed in head and neck squamous cell carcinoma (HNSCC); and regulates tumor progression and response to therapy.
|
29231907 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We investigated genetic variations of c-CBL in HNSCC and the relationship between c-CBL and MET expression.
|
27244893 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining of CD44, p16, EGFR, and c-MET was performed on 105 locally advanced HNSCC patients treated with chemoradiation.
|
27442811 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, overexpression of EGFR and c-MET was observed in HNSCC clinical specimens.
|
27169691 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
|
26832731 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Emerging evidence indicates that hepatocyte growth factor receptor (or Met) pathway plays a pivotal role in HNSCC metastasis and resistance to chemotherapy.
|
23226095 |
2012 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Eighty-four percent of the HNSCC samples showed MET overexpression, whereas 18 of 20 HNSCC cell lines (90%) expressed MET.
|
19318576 |
2009 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The observed association between MET Y1253D-activating point mutation and decreased distant metastasis-free survival in advanced HNSCC suggests that MET may be a potential target for specific treatment interventions.
|
19639388 |
2009 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
For the MET proto-oncogene, which showed low expression in the chemosensitive cell lines, we did immunohistochemical staining on SCCHN of 29 patients who received induction chemotherapy.
|
15623595 |
2004 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases.
|
10861506 |
2000 |
|
Squamous cell carcinoma of the head and neck
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|